Stockreport

DURECT Corporation Announces Top-Line Results from Phase 2a Clinical Trial in Patients with Psoriasis

DURECT Corporation  (DRRX) 
Last durect corporation earnings: 3/3 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: durect.com/investors
PDF CUPERTINO, Calif., Jan. 2, 2020 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced the results from its Phase 2a clinical trial of DUR-928 in patients wit [Read more]